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a b s t r a c t
Numerous studies have explored whether the antibody response to inﬂuenza vaccination in elderly
adults is as strong as it is in young adults. Results vary, but tend to indicate lower post-vaccination
titers (antibody levels) in the elderly, supporting the concept of immunosenescence—the weakening of
the immunological response related to age. Because the elderly in such studies typically have been vac-
cinated against inﬂuenza before enrollment, a confounding of effects occurs between age, and previous
exposures, as a potential extrinsic reason for immunosenescence.
We conducted a four-year study of serial annual immunizations with inactivated trivalent inﬂuenza
vaccines in 136 young adults (16 to 39 years) and 122 elderly adults (62 to 92 years). Compared to data
sets of previously published studies, which were designed to investigate the effect of age, this detailed
longitudinal study with multiple vaccinations allowed us to also study the effect of prior vaccination
history on the response to a vaccine.
In response to the ﬁrst vaccination, young adults produced higher post-vaccination titers, accounting
for pre-vaccination titers, than elderly adults. However, upon subsequent vaccinations the difference
in response to vaccination between the young and elderly age groups declined rapidly. Although age
is an important factor when modeling the outcome of the ﬁrst vaccination, this term lost its relevance
with successive vaccinations. In fact, when we examined the data with the assumption that the elderly
group had received (on average) as few as two vaccinations prior to our study, the difference due to age
disappeared.
Our analyses therefore show that the initial difference between the two age groups in their response to
vaccination may not be uniquely explained by immunosenescence due to ageing of the immune system,
but could equally be the result of the different pre-study vaccination and infection histories in the elderly.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).. IntroductionThe World Health Organization and many national health
uthorities recommend yearly inﬂuenza vaccination for people at
isk of developing serious complications, including elderly persons
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.0/).over a deﬁned age limit (typically 60 or 65 years). Various stud-
ies have described lower serological responses to vaccination in
elderly than in young human adults [1–4]. For example, Beyer et al.
[5] described how ten studies revealed a better immune response
in young subjects than in elderly, 16 could not detect a signiﬁcant
difference, and four found an increased response in the elderly.
Another quantitative meta-analysis of 31 studies consistently
found lower seroprotection and seroconversion rates in the elderly
compared toyounger adults [6], ﬁndings that are in agreementwith
results fromadatabaseof 48 serological trials performed for regula-
tory purposes [6,7]. Thusmost but not all published studies of sero-
logical comparisons report a lower antibody response to inﬂuenza
vaccination in the elderly than in the young adults. A weakened
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Table 1A
Numbersof volunteers, according to age, year of entering the study, andvaccinations
within the study. The table also shows the compliance of participants during the
study. For example, the cohort of young adults started with 55 young individuals in
year 1 (1996), of whom 30 also participated in the second year, 22 in the third year,
and 18 in the ﬁnal year (diagonal).
Age group Number of
vaccinations (NV)
Number of vaccination events
1996 1997 1998 1999 All
Young
adults
1 55 25 32 24 136
2 30 14 15 59
3 22 8 30
4 18 18
All 55 55 68 65 243
Elderly
adults
1 33 42 32 15 122
2 27 38 25 90
3 24 32 56
4 21 21
All 33 69 94 93 289
Table 1B
Vaccine strain for each year and subtype for both age groups. Vaccine and titra-
tion strains were taxonomically identical, except for the A-H1N1 subtype in 1997
(vaccine: A/Beijing/262/95, titration: A/Johannesburg/33/94).
Year A-H3N2 A-H1N1 B
1996 Nanchang/933/95 Texas/36/91 Harbin/7/94
1997 Nanchang/933/95 Beijing/262/95 Harbin/7/94A. Mosterín Höpping et a
mmunological response related to age is known as immunosenes-
ence, and this explanation is commonly used to explain the lower
ntibody response in elderly cohorts to vaccination.
Here we consider two different mechanistic drivers for
mmunosenescence. One mechanism concerns intrinsic drivers
owards immunosenescence based on the ageing of the immune
ystem, a complex process that is not yet fully understood, andmay
nvolve the age-dependent functioning of T-cells and a decreased
utputofnaïveT-cells as a result of involutionof the thymus [8–11].
uch an intrinsic immunosenescent process has been observed
n studies of inﬂuenza-naïve rhesus macaques, where ageing
esults in declined antibody response to inﬂuenza vaccination
12,13].
The effects of such intrinsic immunological drivers may
e compounded by extrinsic, or environmental, drivers of
mmunosenescence. An example of such an environmental con-
ribution towards immunosenescence in reactions to inﬂuenza
accine is previous infection with cytomegalovirus (CMV). CMV
ntibodies have been reported to increase pro-inﬂammatory
otential, which contributes to unresponsiveness of the immune
ystem. Because the presence of CMV antibody strongly corre-
ates with age, this would also explain lower serological responses
o vaccination against inﬂuenza in the elderly [14–16]. Simi-
arly, studies on the effect of repeated vaccination in the elderly
ave proposed the explanation that prior vaccination may attenu-
te subsequent immune responses upon re-exposure to inﬂuenza
17,18].
Because humans partaking in vaccination studies are not naïve
o inﬂuenza infection and their history of vaccination prior to
nrollment is typically unknown, it is difﬁcult to establish the
elative contribution and possible interdependence of age and
xposure history on immunosenescence. We designed a four-
ear cohort vaccination study to delineate the intertwined effect
f age and repeated exposures on the response to inﬂuenza
accination.
. Materials and methods
.1. Subjects and study design
The study was performed from 1996 to 1999 in healthy
ommunity-dwelling young and elderly adults living in Hampton
oads, Virginia, United States. The young adults had never received
nﬂuenza vaccine, and older adults may have been vaccinated pre-
iously, but not for at least twoyears prior to their enrollment in the
tudy. Subjects consented upon enrollment to participation for the
uration of the study. The Institutional Review Board of Eastern
irginia Medical School, Norfolk, VA, approved the study proto-
ol and informed consent form. All study participants received an
ntramuscular injection of the standard dose of trivalent seasonal
nﬂuenza vaccine (Fluzone®, Sanoﬁ) in each of the study years in
hich they were enrolled. The health status of all participants of
oth age groups was very good. All subjects were contacted in the
all of each year to schedule a vaccination visit. Post-vaccination
ollow-upvisitswere scheduled inOctober of each year. Blood sam-
les included5 cm3 of serumcollected just prior to vaccination, and
our weeks post-vaccination.
142 healthy young adults (20–40 years) and 122 healthy older
dults (≥65 years) completed the study, i.e., their sequence of vac-
inations was uninterrupted during the years, and their pre- and
ost-vaccination antibody titers were available for all vaccination
vents and inﬂuenza strains involved. The twoagegroups consisted
f four cohorts each, as each year a new cohort of young and elderly
dults entered the study. Table 1A shows the numbers of vacci-
ees per year and cohort. The vaccine strains changed once for1998 Sydney/5/97 Beijing/262/95 Harbin/7/94
1999 Sydney/5/97 Beijing/262/95 Yamanashi/166/98
each of the three (sub)types in the course of the study, as shown in
Table 1B.
2.2. Serum antibody titers
Hemagglutination inhibitionassays (HIA)wereperformedusing
a single stock source for each of the hemagglutinin antigens (sup-
plied by Centers for Disease Control) and representing the strains
of virus contained in the vaccine. HIA was performed as previ-
ously described [19] using two-fold dilutions of serum from 1/10
to 1/1024. Titers of <1/10 were calculated as 1/5. Geometric mean
titers were calculated using log conversion for each dilution.
2.3. Linear regression models
Heteroscedasticity robust ordinary least squares, a type of linear
regressionmodel, was used to determine the effects of age and vac-
cination history on individual post-vaccination titers, Tpost, using
the heteroskedasticity robust regression (option r) in Stata 12 soft-
ware. In all calculations pre- and post-vaccination HI titers (Tpre-
and Tpost-values) were log2-transformed logarithms of measured
titer levels. For an undetectable HI titer (<10, indicating a ‘seroneg-
ative’ person), a value of 5was imputed. Group log titermeanswere
re-exponentiated and presented as geometric mean titers GMTs
throughout the text.
The initial regression model was Tpost =A+Bpre * Tpre, where A
is the y-axis intercept, Tpre the pre-vaccination titer, and Bpre
the regression coefﬁcient (additional increase in Tpost per unit
increase of Tpre). Subsequently, age group (G: young adults = 0,
elderly adults = 1) and number of vaccinations within the study
(NV: values from 1 to 4) were then added to the regression mod-
els as independent variables: Tpost =A+Bpre * Tpre +Bagegroup *G and
Tpost =A+Bpre * Tpre +Bagegroup *G+Bnv *NV. The respective regres-
sion coefﬁcients were designated Bagegroup and Bnv. All analyses
were run for the three virus (sub)types separately, and for all
(sub)types combined.
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. Results
.1. The effects of previous vaccinations and age on response to
accination
We studied the antibody levels from individuals vaccinated as
art of the four year cohort, based on their hemagglutination inhi-
ition (HI) assay titers. Fig. 1 shows the geometricmean titer (GMT)
alues by vaccine (sub)type, year and cohort. When all titers were
rouped without distinction by virus (sub)type, cohort, or trial
ear, the pre-vaccination GMTs were virtually identical in both age
roups (16.4 in young adults versus 15.5 in elderly adults), but the
ost-vaccination GMTs were a little over twice as high in the young
dults (80.3) than in the older adults (38.8), indicating an age effect.
he A/H1N1 subtype was associated with a much larger age group
atio (3.1 ratio) than the other two vaccine components (1.6 ratio
or A-H3N2 and 1.8 ratio for B).A ﬁrst look at the effect of age as an explanatory variable in
egression models of the response to vaccination suggests that age
s an important determinant of the titer increase induced by vac-
ination. In the regression model including only pre-vaccination
Table 2
Regression analysis. Predicting post vaccination titer, by pre vaccinatio
Independent
variables
Estimates of regression model
Pre-titer A (y-intercept) 2.433***
Bpre 0.600***
R2 0.257
* Notice that the inclusion of age as an independent variable contrib
*** P<0.001.
Table 3
Results of regression models with post vaccination titer Tpost as the de
Variables Estimates of regression model
Nr vaccinations A (y-intercept)
BNV −0.369*
R2 0.039
Pre-titer A (y-intercept) 2.433*
Bpre 0.600*
R2 0.257
Pre-titer A (y-intercept) 2.993
Age group Bpre 0.592*
Bagegroup −1.006*
R2 0.335
Tˆhe regression models on the right include number of previous vacci
statistically signiﬁcant negative effect and contributes to the R2 in eve
* P<0.001.ination data per year. There are two data points for each year in the plots, the ﬁrst
range represent changes in vaccine strain. (For interpretation of the references to
titers as an independent variable to predict the post-vaccination
titers, the predictive power of themodel (R2) is 23.7%, but increases
by about 7% when age is included (Table 2).
As also reported in other studies [1,4,20], we ﬁnd that the num-
ber of previous vaccinations received also has an effect on the titer
increase in response to vaccination. Table 3 shows in its top section
that number of vaccinations alone can explain 4% of the variance in
post-vaccination titers. In a regression model with pre-vaccination
titer as a predictor of post-vaccination titer, the number of previ-
ous vaccinations adds 7% to thepercentage of variance explainedby
themodel, and in a regressionmodelwith pre-vaccination titer and
age group as predictors of post-vaccination titer, number of previ-
ous vaccinations adds a further 6% to the percentage of variance
explained.
3.2. The age difference is limited to a difference between age
groupsAge appears to be an important factor determining the post-
vaccination titer, based on the pre-vaccination titer and number
of vaccinations. We subsequently wanted to test if this age effect
n titer (left), including age as an independent variable (right)*.
Independent
variables
Estimates of regression model
Pre-titer A (y-intercept) 3.535***
Bpre 0.594***
Age BAge −0.021***
R2 0.328
utes a highly signiﬁcant effect and increases the R2.
pendent variable in every caseˆ.
Variables Estimates of regression model
3.738*
Pre-titer A (y-intercept) 2.777*
Bpre 0.642*
Nr vaccinations BNV −0.502*
R2 0.327
Pre-titer A (y-intercept) 3.248*
Age group Bpre 0.692*
Bagegroup −0.911*
Nr vaccinations BNV −0.448*
R2 0.390
nations BNV. Notice that number of previous vaccinations has a
ry case.
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accination GMTs, per (sub)type and decade of age.While there is a
lear difference between the two age groups, there is little variation
n the response to vaccination within each of the two age groups.
Table 4
Summarized results of the regression post-vaccination titer =A+BAge * A
Independent
variables
Estimates of reg
Old adults
Age A (y-intercept) 3.330*
BAge 0.006 (P=0.490
R2 0.001
* Notice that age only has a predictive effect in the combined datasecine 34 (2016) 540–546 543
In particular, the very old persons (84–94 years old) reacted simi-
larly to vaccination as the other elderly persons (60–83 years old).
It is worth noting however that there are only 13 individuals in the
84–94 grouping, and that these elderly may be ﬁtter than average
as this study deliberately only includes ambulatory elderly.
The difference in the effect of age within age group versus
between age groups is also seen in the linear regression analyses
shown in Table 4. Age is an insigniﬁcant factor when regress-
ing post-vaccination titer on pre-vaccination titer and age within
either of the two age groups: it explains none of the variation in
post-vaccination titer data. However, in the dataset comprising
all individuals from both age groups, age can explain 7.6% of the
observed post-vaccination titer variation. In summary, we ﬁnd no
effect of age on post-vaccination titer within the age groups, but a
marked effect between the two age groups.
3.3. The effect of the number of previous vaccinations on the
response to vaccination
The previous analyses suggest that age is an important determi-
nant of the response to vaccination, but the difference in response
to vaccination is only present between age groups. Since young
and elderly groups also differ in their vaccination history and
because the results in Table 3 indicated that the number of previ-
ous vaccinations inﬂuences the response to vaccination, we further
investigated the individual responses in relation to the number of
administered vaccinations for each person.
Table 5A lists, for each number of previous vaccinations, the
results of regressions where the post-vaccination titer was pre-
dicted from pre-vaccination titer and an “age group” term (young
or old). In this analysis the ﬁrst regression uses the ﬁrst vaccina-
tion event recorded for all individuals, the second regression uses
the second vaccination event for all those individuals that have a
second vaccination, and so on until the fourth regression which
only includes the ﬁrst cohort, because this is the only cohort that
is vaccinated four times. It can be seen in Table 5A that as sub-
jects in the elderly adult group enter the study in any of the four
years and receive their ﬁrst vaccination, their post-vaccination titer
will be signiﬁcantly lower than the average post-vaccination titer
for young adults and elderly combined (Bagegroup equals −1.46 2-
fold HI units). As the vaccination history of the elderly and young
groups converges over 2nd, 3rd and4th vaccinations, the difference
caused by age status declines monotonically from −1.46 to −0.43
to −0.16 to 0.075, and age group as a predictor of post-vaccination
titer gradually becomes insigniﬁcant.
Comparing the regression results of Table 5B with those of
Table 5A similarly shows the vanishing age effect: this comparison
reveals that age group adds to the explanatory power of the model
in the ﬁrst vaccination event, because the R2 increases from 0.16
to 0.29 when we include age group in the model predicting the
post-vaccination titer from the pre-vaccination titer for the ﬁrst
vaccination. In the second vaccination event the difference only
increases from 0.40 to 0.42, and for the third and fourth events the
effect of age on the regression model has completely disappeared.
Fig. 3 shows theagegroup ratios of youngadult post-vaccination
titers to elderly adult post-vaccination titers by number of
ge for each of the two age groups, and for the combined dataset.*
ression model
Young adults All
3.909* 4.565*
) 0.003 (P=0.739) −0.022 (P=0.000)
0.000 0.077
t and not within either age group.
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Table 5A
Regression analysis predicting post-titer, by pre-titer and including age group, by number of vaccinationsˆ.
Independent
variables
Estimates of
regression model
Number of vaccinations (NV)
Total 1 2 3 4
Pre-titer
Age group
A (y intercept) 2.43*** 3.54*** 2.36*** 1.79*** 1.04***
Bpre 0.60** 0.65*** 0.60*** 0.68*** 0.84***
Bagegroup −1.46*** −0.43** −0.16 0.075
R2 0.29 0.42 0.46 0.73
ˆNotice that the signiﬁcance for age-group, and the difference inR2betweenTable 4A andTable 4Bdeclinewith number of vaccinations.
** P<0.01.
*** P<0.001.
Table 5B
Regression analysis predicting post-titer, by pre-titer and excluding age group, by number of vaccinations.
Independent
variables
Estimates of
regression model
Number of vaccinations (NV)
Total 1 2 3 4
Pre-titer A (y intercept) 2.43*** 3.00*** 2.03*** 1.69*** 1.09***
Bpre 0.60** 0.56*** 0.64*** 0.69*** 0.84***
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** P<0.01.
*** P<0.001.
accinations, for all three virus (sub)types. Because these age-
roup titer ratios may be biased by pre-vaccination level, as mean
re-vaccination titers generally rise with increasing number of
accinations, we adjusted post-vaccination titers to correct for pre-
accination titer levels using the Bpre estimates of the regression
odels [21]. The resulting adjusted age group titer ratios shown
n Fig. 3 (red) become more precise, as seen by narrower conﬁ-
ence intervals, than the unadjusted age group post-vaccination
iter ratios. The age effect is observed for the ﬁrst vaccination, yet
eclines after further vaccinations, though not monotonically, for
ll (sub)types. For A/H3N2, it takes only two vaccinations for the
wo age groups’ serological responses to converge, and for A/H1N1,
ourvaccinations. The samepatternofdecliningdifferencebetween
ge groups with successive vaccinations is evident in a graph of the
ifference between the intercepts of the regression model post-
accination titer =A+B* pre-vaccination titer, per age group and
er cohort for the two age groups (Supplementary Fig. S1).
.4. The two variables age and number of previous vaccinations
re confounded
The younger adults in our study had never been vaccinated
gainst inﬂuenza; the elderly adults may have received multiple
nﬂuenza vaccinations up to two years before the study. The two
ge groups start with a clear difference in post-vaccination titer
evel after the ﬁrst vaccination within the study, which may be
ttributable to this difference in vaccination history, rather than
ge: the age termwill proxy someof thenegative effect attributable
o previous vaccination history. Since there is no parameter that
ndependently captures history, the exposure history difference
ill be attributed to the only parameter that distinguishes the
wo groups, namely age. Thus, we next investigated whether the
bserved age difference is likely to be caused by age per se (intrin-
ic immunosenescence), or by the extrinsic effect of these previous
accinations.
Aswe have seen in Table 5A and Fig. 3, once individuals received
wo or more vaccinations within the study, the age effect disap-
eared. We therefore tested if the regression model could be used
o estimate the unknown number of previous vaccinations in the
lderly group. To this end,we varied the regressionmodel as shown
n Table 2 (right side) by replacing the number of vaccinations
NV) with a new variable, the augmented number of vaccinations
NVaug). For young adults, NVaug was the same as NV because these0.16 0.40 0.46 0.73
people had not been vaccinated prior to the study; for elderly
adults however, NVaug was set to NV+2 to account for vaccinations
received prior to the study.
Table 6 shows the regression results using the augmented num-
ber of previous vaccinations, and can be compared with Table 2
(right side), the same regressionmodel using thedocumented, non-
augmented number of previous vaccinations. The estimates for the
y-intercept, the slopes for pre-vaccination titers and (augmented)
number of vaccinations, and R2 were exactly the same in Table 6
and Table 2. However, the age group coefﬁcient changed dramati-
cally: it was highly negative in the non-augmented model (−0.911,
P<0.001), but close to zero and insigniﬁcant in the augmented
model (−0.014, P=0.893).
Comparison of these tables therefore demonstrates that age
loses signiﬁcance as a predictor of the response to vaccination,
whilst the R2 increases when using the augmented number of pre-
vious vaccinations. A number of previous vaccinations augmented
by anywhere between 1.3 and 2.3 has the same explanatory effect
as a combination of the documented number of previous vaccina-
tions and age group (Supplementary Table S1 and Supplementary
Fig. S2). These results show that the inﬂuence of age per se dis-
appears when supposing two previous vaccination events in the
elderly before entering the study, and that age as a predictor of
the antibody titer in response to vaccination is thus equivalent to
vaccination history.
4. Discussion
When antibody response after a single vaccination is studied in
groups of young and elderly adults, usually a clear differencewith a
larger response to vaccination in young adults is observed. Impor-
tantly, in our study as well as many others, elderly participants had
already been vaccinated against inﬂuenza prior to the study, to var-
ious degrees, and young participants usually had not. At least since
the 1980s, vaccination of the entire elderly population is a common
target in many developed and developing countries [22], where
such vaccination studies are performed. Thus, it is difﬁcult to enroll
representative, previously unvaccinated, groups of elderly persons.
As a result, any effect of age on the immune response is intrinsically
correlated and necessarily closely linked to vaccination history.
The present cohort study where individuals were repeatedly
vaccinated allowed us to analyze the effect of repeated vaccina-
tion separately from the effect of age in the same cohort study.
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Fig. 3. Young adults’ post-vaccination titers as multiples of elderly adults’ post-
vaccination titers according to virus (sub)type and number of vaccinations, raw
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Table 6
Regression analysis on post-vaccination log titer, by pre-vaccination log titer, aug-
mented number of vaccinations, and age groupˆ.
Variables included Estimates of regression model
Pre-titer A (y-intercept) 3.696*
Bpre 0.630*
Augmented number of
vaccinations
BNVaug −0.448*
Age group Bage −0.014 (P=0.893)
R2 0.390
Nˆotice that the coefﬁcient on age group becomes insigniﬁcant when the augmented
Research and Surveillance contracts HHSN266200700010C andblue) and adjusted for pre-vaccination log titer (red). (For interpretation of the
eferences to color in this ﬁgure legend, the reader is referred to the web version of
his article.)
sing these data, we inferred the effect of repeated exposure on
he response to vaccination, and showed that only twovaccinations
rior to the study can account for the entire observed difference
etween the young and elderly age groups.
A limitation of this study is the lack of reliable infection his-
orypreceding this experiment,which is expected todiffer betweennumber of previous vaccinations is included.
* P<0.001.
the age groups, and the lack of data on post-vaccination infection.
Serum antibody titers are a standard accepted [23] though indirect
and necessarily imperfect measure of vaccine efﬁcacy.
When an analysis leaves out an important explanatory factor,
an omitted variable bias is created. Regression models compen-
sate for the omitted variable by over- or underestimating included
explanatory variables that are correlatedwith the omitted variable.
In the present case, the lack of a variable for number of previous
vaccinations is compensated for by a distortion in the correlated
age variable. As a result, being elderly appears to be a determinant
of the antibody response to vaccination, whereas at least part of
actual determinant could be vaccination history. It should also be
noted that any source of difference in exposure history, including
prior infections, may lead to a similar situation, in which age and
exposure history are confounded.
Our results are in line with previous studies, describing a
weakened serological response to vaccination in elderly adults,
i.e. an immunosenescent effect. However, we put forward the
explanation that, in addition or instead of resulting from intrin-
sic ageing of the immune system, this immunosenescence effect
could be enhanced, or more parsimoniously explained by an
extrinsic driver: the previous vaccination and infection history
of the elderly group, related to the yearly inﬂuenza vaccination
campaigns. Of course, we do not deny the general existence of
immunosenescence. It is well established that ageing modulates
many immune functions. However, given the well-documented
inﬂuence of repeated vaccination [20,24,25], it seems that com-
parative serological data sets containing an elderly group with an
undocumented number of previous vaccinations prior to enroll-
ment, and a vaccination-free young group, is an inaccurate way
to explore immunosenescence. Indeed, a simple age effect would
not explain how the titer difference between age groups changes
for subsequent vaccinations. In our view, carefully controlled stud-
ies are needed to establish the effect of immunosenescence in
this context, studies where either vaccination and infection history
among the two age groups is comparable, or sufﬁcient information
on the history is known such that differences can be controlled
for.
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